| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2003;76:1643-1649
© 2003 The Society of Thoracic Surgeons
a Department of General Surgery, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
Accepted for publication May 12, 2003.
* Address reprint requests to Dr López-Cano, Department of General Surgery, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, E-08035 Barcelona, Spain.
e-mail: lopezc{at}hg.vhebron.es
BACKGROUND: Myasthenia gravis is by far the most common paraneoplastic syndrome of thymomas. There is little information regarding the influence of clinical variables and thymoma-associated factors on biologic development of myasthenia gravis. The aim of the study was to determine independent predictors of clinical outcome in thymoma with myasthenia gravis.
METHODS: We studied 108 patients with thymoma-associated myasthenia gravis undergoing removal of the mediastinal mass between 1967 and 2000. Clinical and pathologic variables associated with clinical outcome of myasthenia were assessed by multivariate Cox regression analysis.
RESULTS: Patients were followed for a mean period of 10 years (9 months to 33 years). A total of 38 patients died (35.2%), in 14 cases (37%) because of myasthenia gravis and in 6 (16%) because of recurrence of thymoma. With respect to clinical outcome of myasthenia gravis, at the end of the follow-up period, the rate of remission was 16% (n = 17). Of the 91 patients in whom remission was not achieved, 55 had no symptoms with immunosuppressive medication and 36 had symptoms with medication.
CONCLUSIONS: In patients with thymoma-associated myasthenia gravis, well-differentiated thymic carcinoma (Müller-Hermelink system), age more than 55 years, and interval from the onset of symptoms to thymectomy of less than 1 year were found to be independent predictors of nonremission of myasthenia gravis after thymectomy.
This article has been cited by other articles:
|
|
 |
|
  J. M. Ponseti, J. Gamez, R. Vilallonga, C. Ruiz, J. Azem, M. Lopez-Cano, and M. Armengol Influence of ectopic thymic tissue on clinical outcome following extended thymectomy in generalized seropositive nonthymomatous myasthenia gravis Eur. J. Cardiothorac. Surg., November 1, 2008; 34(5): 1062 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nakajima, T. Murakawa, T. Fukami, A. Sano, S. Takamoto, and H. Ohtsu Postthymectomy Myasthenia Gravis: Relationship With Thymoma and Antiacetylcholine Receptor Antibody Ann. Thorac. Surg., September 1, 2008; 86(3): 941 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-F. Ko, C.-C. Huang, M.-J. Hsieh, S.-H. Ng, C.-C. Lee, C.-C. Lee, T.-K. Lin, M.-C. Chen, and L. Lee 31P MR Spectroscopic Assessment of Muscle in Patients with Myasthenia Gravis before and after Thymectomy: Initial Experience Radiology, April 1, 2008; 247(1): 162 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. K. Park, S. S. Choi, J. G. Lee, D. J. Kim, and K. Y. Chung Complete stable remission after extended transsternal thymectomy in myasthenia gravis. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zisis, D. Rontogianni, C. Tzavara, K. Stefanaki, A. Chatzimichalis, A. Loutsidis, K. Iliadis, A. Kontaxis, T. Dosios, and I. Bellenis Prognostic Factors in Thymic Epithelial Tumors Undergoing Complete Resection Ann. Thorac. Surg., September 1, 2005; 80(3): 1056 - 1062. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
